UK regulatory guide

Are research peptides legal in the UK? A complete 2026 guide

UK law does not ban peptides as a group. Some peptide hormones, such as somatropin and chorionic gonadotrophin (HCG), are Class C controlled drugs under the Misuse of Drugs Act 1971, and regulation 46 of the Human Medicines Regulations 2012 makes it unlawful, with exceptions, to sell or supply, or offer to sell or supply, an unauthorised medicinal product.

Key facts

Regulation 46(1) of the Human Medicines Regulations 2012 (S.I. 2012/1916) provides that a person may not sell or supply, or offer to sell or supply, an unauthorised medicinal product.
Regulation 46(3) provides that a person may not possess an unauthorised medicinal product if the person knows or has reasonable cause to believe that the product is intended to be sold or supplied to another person within the United Kingdom or the European Economic Area.
Regulation 2(1) defines a “medicinal product” to include any substance that may be used by or administered to human beings with a view to restoring, correcting or modifying a physiological function by exerting a pharmacological, immunological or metabolic action.
Somatropin, somatrem, somatotropin and chorionic gonadotrophin (HCG) are Class C drugs in Schedule 2, Part III of the Misuse of Drugs Act 1971. None of the peptides profiled on this site appears by name in that Schedule or in the Home Office controlled drugs list (last updated 1 April 2025).

In practice the answer depends on the substance and on the activity: whether a peptide is a controlled drug, a medicinal product or a psychoactive substance, and whether the question is one of selling, supplying, possessing or importing it. The provisions below say what each statute actually provides, and getting it wrong matters for both researchers and suppliers.

Headline position

Which UK laws apply to peptides?

Misuse of Drugs Act 1971

Section 2 and Schedule 2 specify the controlled drugs, in Classes A, B and C. Section 3 restricts importation, section 4 production and supply, and section 5 possession, of controlled drugs. None of the peptides profiled on this site appears by name in Schedule 2.

Human Medicines Regulations 2012

Regulation 46 prohibits selling or supplying an unauthorised medicinal product, and regulation 279 prohibits publishing an advertisement for a medicinal product unless one of the authorisations or registrations it lists is in force. “Medicinal product” is defined in regulation 2(1) by presentation and by function.

Psychoactive Substances Act 2016

Creates offences of producing, supplying, importing or exporting, and possessing with intent to supply, a psychoactive substance, each with a mental element. Schedule 1 exempts controlled drugs and medicinal products; Schedule 2 exempts approved scientific research. Whether a given peptide has a “psychoactive effect” as defined in section 2 is not something this guide decides.

The detail

What is the difference between possessing and supplying peptides?

UK law deals with possession and supply through separate provisions, and which provision applies depends on the substance. Regulation 46(1) of the Human Medicines Regulations 2012 concerns selling, supplying or offering to sell or supply an unauthorised medicinal product. Regulation 46(3) provides that a person may not possess an unauthorised medicinal product if the person knows or has reasonable cause to believe that it is intended to be sold or supplied to another person within the United Kingdom or the European Economic Area.

The Misuse of Drugs Act 1971 restricts supply (section 4) and possession (section 5) only of controlled drugs, and none of the peptides profiled on this site appears by name in Schedule 2. Under the Psychoactive Substances Act 2016, possession is an offence only where it is with intent to supply (section 7) or in a custodial institution (section 9). The frequently asked questions below set out each provision and link to the text of the law.

Importation

Can research peptides be imported into the UK?

The rules that apply to an import depend on the substance. Section 3 of the Misuse of Drugs Act 1971 prohibits importing a controlled drug. Regulation 17(1) of the Human Medicines Regulations 2012 provides that a person may not, except in accordance with a manufacturer’s licence, import a medicinal product into Great Britain from a country other than Northern Ireland or an approved country for import, and regulation 17(6) provides that this does not apply to a person who imports a medicinal product for administration to himself or herself or to a member of that person’s household. Section 8 of the Psychoactive Substances Act 2016 creates a separate offence of importing a psychoactive substance.

The MHRA’s guidance for UK wholesalers and manufacturers says that importing an unlicensed medicine requires a Manufacturer’s ‘Specials’ Licence or a Wholesale Dealer’s Licence, and that the MHRA must be notified before the import. The frequently asked questions below link to each of these sources. This guide does not say whether any particular shipment is lawful.

The MHRA position

What is the MHRA's role in regulating unlicensed medicines?

The Medicines and Healthcare products Regulatory Agency (MHRA) regulates medicines, medical devices and blood components for transfusion in the UK, and is an executive agency sponsored by the Department of Health and Social Care (GOV.UK).

The MHRA’s guidance for UK wholesalers and manufacturerssays that importing an unlicensed medicine requires a Manufacturer’s ‘Specials’ Licence or a Wholesale Dealer’s Licence, and that the MHRA must be notified before the import. Its guidance on unlicensed ‘specials’describes them as products specially manufactured or imported for the treatment of an individual patient after being ordered by a prescriber.

On enforcement, the MHRA publishes press releases. InOperation Pangea XVIII(10 to 23 March 2026) the MHRA, UK Border Force and international partners seized over two million doses of illicit medicines; over half were controlled drugs and the remainder were prescription-only medicines in the UK. The MHRA’s Criminal Enforcement Unit also took action against websites, social media accounts and marketplace listings. The release names sedation, pain relief and treatments for erectile dysfunction as the products most commonly intercepted and does not mention research peptides.

This guide does not summarise how the MHRA treats research peptides specifically. To ask, seeContact the MHRA.

UK vs EU vs US vs Russia

How does the UK position compare with the EU, US and Russia?

United Kingdom

Controlled drugs are those specified in Schedule 2 to the Misuse of Drugs Act 1971. Selling or supplying an unauthorised medicinal product is prohibited by regulation 46 of the Human Medicines Regulations 2012. The Psychoactive Substances Act 2016 creates separate offences, with its own exemptions.

European Union

The EMA publishes a list of centrally authorised medicines. Of the peptides profiled on this site it lists Ozempic, Rybelsus and Wegovy (semaglutide) and Victoza and Saxenda (liraglutide) as authorised, for example Ozempic andVictoza, andEgrifta (tesamorelin) as application withdrawn. Authorisations granted by individual member states were not checked.

United States

Under 21 U.S.C. 355(a), no person may introduce or deliver for introduction into interstate commerce any new drug unless an approval of an application filed under subsection (b) or (j) is effective for it. Drugs@FDA lists approved products for some peptides profiled here, includingOzempic,Egrifta (tesamorelin) andForzinity (elamipretide).

Russia

The Russian drug reference Vidal.ru listsSemax nasal drops under registration numbers ЛП-№(009449)-(РГ-RU) and ЛП-№(010596)-(РГ-RU) andSelank nasal drops under registration number ЛП-№(010951)-(РГ-RU). Its Semax page marks the product as dispensed by prescription (“Препарат отпускается по рецепту”). The state register of medicines was not queried for this guide.

FAQ

Frequently asked questions

Are peptides legal in the UK?

Are research peptides illegal in the UK?

Not as a class. None of the peptides profiled on this site appears by name in Schedule 2 to the Misuse of Drugs Act 1971, which specifies the controlled drugs. The medicines rules work differently: regulation 46(1) of the Human Medicines Regulations 2012 provides that a person may not sell or supply, or offer to sell or supply, an unauthorised medicinal product, and regulation 2(1) defines a ‘medicinal product’ to include any substance that may be used by or administered to human beings with a view to restoring, correcting or modifying a physiological function by exerting a pharmacological, immunological or metabolic action. Whether a particular peptide is an unauthorised medicinal product depends on that product, and this guide does not decide it for any individual peptide. Some peptides profiled on this site, such as semaglutide and liraglutide, are authorised UK medicines (MHRA Drug Safety Update).

Can I import research peptides into the UK?

Which law applies depends on the substance. Section 3 of the Misuse of Drugs Act 1971 prohibits the importation of a controlled drug, and none of the peptides profiled on this site appears by name in the Act’s Schedule 2. Regulation 17(1) of the Human Medicines Regulations 2012 provides that a person may not, except in accordance with a manufacturer’s licence, import a medicinal product into Great Britain from a country other than Northern Ireland or an approved country for import; regulation 17(6) provides that this does not apply to a person who imports a medicinal product for administration to himself or herself or to a member of that person’s household. The MHRA’s guidance for UK wholesalers and manufacturers says that importing an unlicensed medicine requires a Manufacturer’s ‘Specials’ Licence or a Wholesale Dealer’s Licence, and that the MHRA must be notified before the import. Separately, section 8 of the Psychoactive Substances Act 2016 makes importing a psychoactive substance an offence where the person knows or suspects, or ought to know or suspect, that it is one and intends to consume it, or knows or is reckless as to whether another person is likely to consume it, for its psychoactive effects. This guide does not say whether any particular shipment is lawful.

Is Semax legal in the UK?

Semax does not appear by name in Schedule 2 to the Misuse of Drugs Act 1971, so that Act’s controls on controlled drugs do not apply to it as a named substance. Under regulation 46(1) of the Human Medicines Regulations 2012 a person may not sell or supply, or offer to sell or supply, an unauthorised medicinal product. A medicinal product is unauthorised if none of the authorisations or registrations listed in regulation 46(6) is in force for it in the country where it is intended to be sold or supplied, and regulation 46 is subject to the exceptions in Part 10 of the Regulations (regulation 46(7)). Whether an authorisation is in force for a product can be checked on the MHRA Products database.

What is the difference between possession and supply?

They are dealt with by separate provisions, and which provision applies depends on the substance. Regulation 46(1) of the Human Medicines Regulations 2012 concerns selling, supplying or offering to sell or supply an unauthorised medicinal product; regulation 46(3) provides that a person may not possess an unauthorised medicinal product if the person knows or has reasonable cause to believe that it is intended to be sold or supplied to another person within the United Kingdom or the European Economic Area. Under the Misuse of Drugs Act 1971, section 5(1) provides that it is not lawful to have a controlled drug in one’s possession and section 4(1) that it is not lawful to produce, supply or offer to supply one; both apply only to controlled drugs. Under the Psychoactive Substances Act 2016, possession is an offence only where it is with intent to supply (section 7) or in a custodial institution (section 9).

Could a peptide become a controlled drug?

Yes. Section 2(2) of the Misuse of Drugs Act 1971 allows Schedule 2 to be amended by Order in Council to add a substance or product to Part I, II or III (Class A, B or C). Under section 2(5) a draft of the Order must be approved by a resolution of each House of Parliament, and the Secretary of State may not lay it except after consultation with, or on the recommendation of, the Advisory Council on the Misuse of Drugs. The Council’s duty under section 1(2) includes keeping under review drugs which are being or appear likely to be misused and whose misuse is having or appears capable of having harmful effects sufficient to constitute a social problem. The Home Office states that its controlled drugs list is not exhaustive, so check the Act’s Schedule 2 itself.

Does the Psychoactive Substances Act 2016 cover peptides?

Section 2 defines a ‘psychoactive substance’ as any substance that is capable of producing a psychoactive effect in a person who consumes it and is not an exempted substance; a substance produces a psychoactive effect if, by stimulating or depressing the person’s central nervous system, it affects the person’s mental functioning or emotional state. Schedule 1 exempts controlled drugs, medicinal products, alcohol and alcoholic products, nicotine, tobacco products, caffeine and caffeine products, and food (each as defined in the Schedule). Its entry for medicinal products uses the meaning in regulation 2 of the Human Medicines Regulations 2012, which does not depend on a medicine being licensed. The Act creates offences of producing (section 4), supplying or offering to supply (section 5), possessing with intent to supply (section 7), importing or exporting (section 8) and possessing in a custodial institution (section 9), each depending on what the person knows, suspects or intends about consumption for psychoactive effects. Schedule 2 exempts certain activities, including activity carried on in the course of, or in connection with, ‘approved scientific research’, meaning research carried out by a person who has approval from a relevant ethics review body. Whether a particular peptide meets the section 2 definition is not something this guide decides.

Is there a UK researcher’s licence for peptides?

The provisions cited on this page refer to research only in specific ways, not as a general licence. The Psychoactive Substances Act 2016 exempts activity connected with approved scientific research (Schedule 2, paragraph 4). Section 3(2)(b) of the Misuse of Drugs Act 1971 permits the importation or exportation of a controlled drug under a licence issued by the Secretary of State. The MHRA’s guidance on importing human medicines sets out the licences needed to import an unlicensed medicine. For advice on a specific project, contact the MHRA directly.

What about prescribing peptides as a UK clinician?

Regulation 167 of the Human Medicines Regulations 2012 provides that the prohibitions in regulation 46 do not apply to a ‘special medicinal product’ where it is supplied in response to an unsolicited order, is manufactured and assembled in accordance with the specification of a doctor, dentist, nurse independent prescriber, pharmacist independent prescriber or supplementary prescriber, and is for use by a patient for whose treatment that person is directly responsible in order to fulfil the special needs of that patient, together with further conditions on supply, advertising, supervision, records and licensing. The MHRA’s guidance on unlicensed ‘specials’ describes them as products specially manufactured or imported for the treatment of an individual patient after being ordered by a prescriber. This guide does not assess any peptide’s suitability for prescribing.

Important caveat

This guide is an educational summary of the UK regulatory framework as it stood at the date of last review. It is not legal advice. The Misuse of Drugs Act, Human Medicines Regulations, and Psychoactive Substances Act are all live statutes, and individual compounds can be added to schedules at any time by statutory instrument. Researchers should verify the current position with primary regulatory sources (MHRA, Home Office controlled-drug schedules) before relying on the position stated here, and should obtain qualified legal advice for any decision with material consequences.

Browse peptide profiles Full site disclaimer

Nootropic Peptides